ArticleVeterinary research communications2026
Residue analysis and determination of withdrawal period of florfenicol upon in-feed administration to striped catfish Pangasianodon hypophthalmus (Sauvage, 1878).
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Florfenicol (FFL) is a broad-spectrum antibiotic to treat bacterial diseases of fish with a recommended dose of 10 mg/kg biomass per day for 10 successive days. This study investigates the accrual depletion of the antibiotic residue in fish tissue when administered at varying dosages and durations in Pangasianodon hypophthalmus. The concentrations of FFL and its major metabolite, florfenicol amine (FFA) exhibited dose- and tissue-dependent accumulation patterns, with peak levels occurring at different sampling points during the dosing period rather than uniformly on a single day. In plasma, maximum FFL concentrations were observed on day 20 in the 1× and 3× groups, whereas in muscle tissues peak levels occurred on day 20 in the 3× and 5× groups. In contrast, kidney and liver tissues generally showed higher accumulation on day 10 of dosing. The kidneys of the 1× group exhibited FFL residues of 372.88 ± 13.20 ng/g on day 10 of FFL administration, which subsequently decreased to 92.00 ± 1.30 ng/g by day 30 of dosing, and further dropped to 8.34 ± 0.70 ng/g on post-FFL dosing day 10. At a therapeutic dosage of 10 mg/kg biomass, the muscle residues in P. hypophthalmus also dropped below the maximum residual limit of 100 µg/kg within 1-day post-dosing. In this investigation, supporting the sanctioned dosage of 10 mg/kg biomass per day for 10 successive days, the noted withdrawal time period was significantly shorter than the recommended 15 days. Following the CVMP protocol, the residues in the muscle of P. hypophthalmus decreased below the MRL value of 100 µg/kg within 1 day (27-degree days, water temperature 27 °C) for the therapeutic dose group. Nonetheless, considering the tolerance limit and a confidence level of 95%, a 5-day (135-degree days) withdrawal period was projected at the therapeutic dosage.
Indexed as
Identifiers
42029852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.